Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and Ritonavir in Relapsed/Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
NCT02948283Phase 1Completed
- Sponsor
- City of Hope
- Start
- Sep 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liquid metformin (Aspargo Labs) and ritonavir in multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), sponsored by City of Hope. Primary endpoint: Incidence of adverse events at 1 year. Started Sep 2017; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)ritonavir
03
Conditions
multiple myeloma (MM)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02948283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02948283.